(Reuters) -Eli Lilly said on Wednesday it is partnering with Walmart to sell its weight-loss treatment Zepbound at the retailer’s pharmacies across the United States at direct-to-consumer prices.
This marks the first time the drugmaker has provided a retail pick-up option to customers who use the LillyDirect website to order Zepbound, it said.
Self-paying customers can get Zepbound single-dose vials in all approved strengths at Walmart pharmacies, with the lowest dose starting at $349 per month, Lilly said.
The drugmaker has been working on expanding access to Zepbound as it competes with rival Novo Nordisk’s Wegovy for a share in the potential $150 billion obesity drug market.
About 35% of new prescriptions of the drug it fulfilled during the second quarter were from cash-paying customers through LillyDirect, the company said.
Recent prescription data shared by analysts indicates Lilly has taken the lead, overtaking Novo despite its initial first-mover advantage.
The companies have also been offering the drugs on several telehealth platforms.
(Reporting by Christy Santhosh in Bengaluru; Editing by Krishna Chandra Eluri and Leroy Leo)
Comments